Witnessing the stock’s movement on the chart, on Tuesday, Bristol-Myers Squibb Co (NYSE: BMY) set off with pace as it heaved 0.31% to $57.76, before settling in for the price of $57.58 at the close. Taking a more long-term approach, BMY posted a 52-week range of $39.35-$61.08.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 16.92% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 5.14%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -87.94%. This publicly-traded company’s shares outstanding now amounts to $2.03 billion, simultaneously with a float of $2.03 billion. The organization now has a market capitalization sitting at $117.51 billion. At the time of writing, stock’s 50-day Moving Average stood at $56.34, while the 200-day Moving Average is $49.26.
Bristol-Myers Squibb Co (BMY) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Drug Manufacturers – General industry. Bristol-Myers Squibb Co’s current insider ownership accounts for 0.08%, in contrast to 77.73% institutional ownership. According to the most recent insider trade that took place on Nov 04 ’24, this organization’s SVP and Controller sold 700 shares at the rate of 55.62, making the entire transaction reach 38,930 in total value, affecting insider ownership by 11,760. Preceding that transaction, on Nov 01 ’24, Company’s EVP,Chief Med.Offr.,Drug Dev. bought 1,830 for 54.67, making the whole transaction’s value amount to 100,055. This particular insider is now the holder of 62,109 in total.
Bristol-Myers Squibb Co (BMY) Earnings and Revenue Records
Bristol-Myers Squibb Co’s EPS decrease for this current 12-month fiscal period is -87.94% and is forecasted to reach 7.08 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -5.00% through the next 5 years, which can be compared against the 5.14% growth it accomplished over the previous five years trading on the market.
Bristol-Myers Squibb Co (NYSE: BMY) Trading Performance Indicators
Let’s observe the current performance indicators for Bristol-Myers Squibb Co (BMY). It’s Quick Ratio in the last reported quarter now stands at 1.09. The Stock has managed to achieve an average true range (ATR) of 1.30. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 2.48. Similarly, its price to free cash flow for trailing twelve months is now 8.51.
In the same vein, BMY’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -3.60, a figure that is expected to reach 1.47 in the next quarter, and analysts are predicting that it will be 7.08 at the market close of one year from today.
Technical Analysis of Bristol-Myers Squibb Co (BMY)
Going through the that latest performance of [Bristol-Myers Squibb Co, BMY]. Its last 5-days volume of 17.38 million indicated improvement to the volume of 14.12 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 70.06% While, its Average True Range was 1.24.
Raw Stochastic average of Bristol-Myers Squibb Co (BMY) in the period of the previous 100 days is set at 77.66%, which indicates a major rise in contrast to 57.63% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 22.38% that was lower than 28.24% volatility it exhibited in the past 100-days period.
